Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis.

ABSTRACT:

Purpose

To examine the associations of palbociclib dose modifications with clinical outcomes of patients with HR+/HER2- metastatic breast cancer (MBC) treated with first-line (1L) palbociclib + aromatase inhibitor (AI) in routine practice.

Methods

Using the Flatiron Health Analytic Database, we conducted a retrospective analysis of HR+/HER2- MBC patients who started 1L palbociclib + AI February 2015-March 2020. Kaplan-Meier analyses were used to estimate treatment duration, real-world progression-free survival (rwPFS), and overall survival (OS) by palbociclib dose adjustments (any change in palbociclib daily dose while on treatment) and dose reductions (starting dose <125 mg/day or dose reduced while on treatment). Cox proportional hazard regression models were performed to

SUBMITTER: Layman RM 

PROVIDER: S-EPMC11986547 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature